Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Richard A. Miller
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 37
- Beta
- 0.87
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 50.41
Financials
Net Income
$-17.96MEBITDA
$-17.19MFree Cash Flow
$-15.98MEPS (diluted)
$-0.19Shares Outstanding (diluted)
92.37M+357.7%Operating Expenses
$19.30MCash & Debt
$215.23MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-15.28M | $-0.19 |
| 2024 | $0.00 | $-62.29M | $-1.02 |
| 2023 | $0.00 | $-27.03M | $-0.56 |
| 2022 | $0.00 | $-41.31M | $-0.89 |
| 2021 | $0.00 | $-43.24M | $-1.03 |
| 2020 | $0.00 | $-6.00M | $-0.20 |
| 2019 | $0.00 | $-46.67M | $-1.49 |
| 2018 | $0.00 | $-46.94M | $-1.71 |
| 2017 | $0.00 | $-55.66M | $-2.72 |
| 2016 | $0.00 | $-36.38M | $-2.36 |
| 2015 | $0.00 | $-31.34M | $-1.54 |
| 2014 | $0.00 | $-176.0K | $-1.03 |
Valuation
CRVShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·5h ago·Neutral
…rker data from the soquelitinib Phase 1 atopic dermatitis trial SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of peer-reviewed final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma.
View source ↗
Earnings
Tue, Nov 3(in 2 months)
Consensus estimate $-0.21 per share
Typical surprise -7.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.19 vs $-0.16miss
- Thu, May 7$-0.15 vs $-0.14miss
- Thu, Mar 12$-0.15 vs $-0.14miss
- Tue, Nov 4$-0.12 vs $-0.14beat
- Thu, Aug 7$-0.10 vs $-0.13beat
- Thu, May 8$-0.13 vs $-0.13beat
Estimates and results for CRVS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CRVS officers and directors.
- Bought
- $13.3m
- Sold
- $9.8m
17 trades
2 trades
- Moore David Scottbought
- Miller Richard A Mdbought
- Miller Richard A Mdbought
- Orbimed Advisors Llcsold
- Thompson Peter A.sold
- Thompson Peter A.bought
- Thompson Peter A.bought
- Orbimed Advisors Llcbought
81 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.